JULY 4TH 2016 Hong Kong, PRC – Luqa Pharmaceuticals (“Luqa” or the “Company”), the China focused specialty pharmaceutical company, announces that it has entered into an exclusive long-term agreement for the distribution rights of ZALAIN (Sertaconazole Nitrate Cream) a product used for the topical treatment of surface skin mycosis developed by Ferrer, being already available in more than 50 countries worldwide.

Sertaconazole is an antifungal medication of the Imidazole class indicated for the treatment of  skin infections such as tinea pedis. With a presence in important international markets, including the USA or Germany, the molecule is well recognised by doctors for its unique safety and efficacy properties.

Luqa will be responsible for the sales, marketing and distribution in China, Hong Kong and Macau with initial commercialisation expected during the second half of 2016. Luqa is already firmly established in the dermatology market with both its prescription and aesthetic dermatology portfolio, which is actively promoted and distributed by the Company’s own sales force across China.

Robert Braithwaite, Luqa’s CEO commented,

“We are extremely pleased to announce this transaction, which extends Luqa’s growing dermatology portfolio, also adding the China rights to those of Hong Kong and Macau. This extends our portfolio of solutions in prescription dermatology and enables us to further leverage our growing sales and marketing infrastructure in Greater China. Luqa will see immediate revenue from the product in the territory, but this will be a key brand for expansion with our sales and marketing dermatology effort going forward.”

Under the terms of the agreement, Luqa has also obtained rights to Zalain Vaginal Ovules, indicated for the treatment of vulvovaginal infections, which will be rapidly relaunched in Hong Kong and Macau in conjunction with the company’s existing pre and post pregnancy portfolio.


About Luqa Pharmaceuticals

Luqa Pharmaceuticals is a China-focused company. It acquires, develops and commercialises innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. Luqa aims to become a leader in specialty care segments in China.

For more information about Luqa Pharmaceuticals

Mr. Luis Juste Business Development Director

+86 15618684311

About Ferrer

Ferrer is a Barcelona-based international pharmaceutical company with 27 worldwide affiliates and a presence in more than 90 countries. It is active in the pharmaceutical, health, fine chemical and food sectors and is committed to the research and development of innovative medicinal products. It has diversified across the whole healthcare spectrum, including prescription drugs, hospital products, medical devices, molecular diagnostics, OTC and self-care.